AstraZeneca Licenses Novel EGFR Inhibitor Zegfrovy from Dizal in Deal Worth Up to $1.5B

summarizeSummary

AstraZeneca enters an exclusive global license for Zegfrovy, an approved oral EGFR inhibitor for lung cancer, paying $600M upfront and up to $900M in milestones.

check_boxKey Events · M&A and Partnerships · AZN

• Global License for Zegfrovy

  AstraZeneca acquires worldwide rights to Zegfrovy (sunvozertinib), an oral EGFR inhibitor, from Dizal Pharmaceutical. The drug is already approved in the US and China for EGFR exon 20 insertion NSCLC after prior therapy.

• Financial Terms

  Upfront payment of $600 million, up to $900 million in development, regulatory, and sales milestones, plus tiered royalties on global sales. The transaction does not impact 2026 guidance.

• First-Line Expansion Potential

  Positive Phase III WU-KONG28 trial results in first-line NSCLC with exon 20 insertion mutations were presented at ASCO 2026. A supplemental New Drug Application has been submitted to the FDA and China's CDE, with Breakthrough Therapy Designation granted.

• Strategic Fit in Lung Cancer Portfolio

  Zegfrovy complements AstraZeneca's existing EGFR-targeted therapies, including Tagrisso, and strengthens its position in the EGFR-mutated NSCLC market, particularly for patients with limited treatment options.

auto_awesomeAnalysis · AZN · Life Sciences

AstraZeneca secures global rights to Zegfrovy, an oral EGFR inhibitor already approved in the US and China for a subset of lung cancer patients. The deal strengthens its leading lung cancer portfolio and adds a near-term commercial asset with potential to expand into the first-line setting. The upfront payment of $600 million and up to $900 million in milestones represent a significant capital commitment, but the drug's existing approvals and positive Phase III data reduce development risk. This is a strategic bolt-on acquisition that complements AstraZeneca's existing EGFR franchise, including Tagrisso.